$14.5 Billion Solstice–Element Merger Ends After Shareholder Pushback
Solstice OKs a $500M buyback and reaffirms 2026 guidance.
Already have an account? Sign in.
Solstice OKs a $500M buyback and reaffirms 2026 guidance.
Novartis and Ionis said pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or deaths in a Phase 3 trial of 8,323 patients.
Canaccord cites tinlarebant as the first drug shown to slow Stargardt lesion growth. The PDUFA date is February 12, 2027.
AMC CEO Adam Aron calls Robinhood’s AMC stock tokens vile and a fake market, demands a halt, and considers an SEC complaint.